Page 1 | Search Results | Diabetes | American Diabetes Association

1-17 of 17

Sort by

Sort Order Select

Meeting Abstracts

1651-P: Elevated FGF21 Levels after Total Pancreatectomy and in Response to Single-Dose Glucagon Receptor Antagonism in Humans

MAGNUS F.G. GRØNDAHL, CAROLINE T. JUEL, ASGER LUND, SOFIE HAEDERSDAL, MARIA M. ANDERSEN, JENS S. SVENNINGSEN, MATTHEW GILLUM, BOLETTE HARTMANN, JENS J. HOLST, TINA VILSBØLL, FILIP K. KNOP

Diabetes 2023;72(Supplement_1):1651-P

https://doi.org/10.2337/db23-1651-P

Published: 20 June 2023

View article titled, 1651-P: Elevated FGF21 Levels after Total Pancreatectomy and in Response to Single-Dose Glucagon Receptor Antagonism in Humans

Meeting Abstracts

801-P: Short-Acting Exenatide Added Three Times Daily to Insulin Therapy Improves Fatty Liver Index in Type 1 Diabetes

NICKLAS JOHANSEN, THOMAS F. DEJGAARD, ASGER LUND, CASPER K. NIELSEN, TINA VILSBØLL, FILIP K. KNOP

Diabetes 2023;72(Supplement_1):801-P

https://doi.org/10.2337/db23-801-P

Published: 20 June 2023

View article titled, 801-P: Short-Acting Exenatide Added Three Times Daily to Insulin Therapy Improves Fatty Liver Index in Type 1 Diabetes

Meeting Abstracts

745-P: Short-Acting Exenatide Added Three Times Daily to Insulin Therapy Improves Insulin Sensitivity in Type 1 Diabetes

NICKLAS JOHANSEN, THOMAS F. DEJGAARD, ASGER LUND, TINA VILSBØLL, HENRIK U. ANDERSEN, FILIP K. KNOP

Diabetes 2022;71(Supplement_1):745-P

https://doi.org/10.2337/db22-745-P

Published: 01 June 2022

View article titled, 745-P: Short-Acting Exenatide Added Three Times Daily to Insulin Therapy Improves Insulin Sensitivity in Type 1 Diabetes

Meeting Abstracts

258-OR: The Glucagonotropic Effect of GLP-2 during Hypoglycemia, Euglycemia, and Hyperglycemia in Healthy Men: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study

NINA L. HANSEN, TORE MAGNUSSEN, JENS J. HOLST, BOLETTE HARTMANN, MIKKEL B. CHRISTENSEN, ASGER LUND, FILIP K. KNOP

Diabetes 2021;70(Supplement_1):258-OR

https://doi.org/10.2337/db21-258-OR

Published: 01 June 2021

View article titled, 258-OR: The Glucagonotropic Effect of GLP-2 during Hypoglycemia, Euglycemia, and Hyperglycemia in Healthy Men: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study

Meeting Abstracts

1192-P: Robust Arginine-Stimulated Glucagon Secretion in Patients with Type 1 Diabetes Independent of Diabetes Duration, Age, HbA1c, and Beta-Cell Secretory Capacity

JULIE WARNØE, NICKLAS J. JOHANSEN, ASGER LUND, JONATAN I. BAGGER, NICOLAI J. WEWER ALBRECHTSEN, SR., BOLETTE HARTMANN, JENS J. HOLST, TINA VILSBØLL, HENRIK U. ANDERSEN, THOMAS F. DEJGAARD, FILIP K. KNOP

Diabetes 2021;70(Supplement_1):1192-P

https://doi.org/10.2337/db21-1192-P

Published: 01 June 2021

View article titled, 1192-P: Robust Arginine-Stimulated Glucagon Secretion in Patients with Type 1 Diabetes Independent of Diabetes Duration, Age, HbA1c, and Beta-Cell Secretory Capacity

Meeting Abstracts

1191-P: Increased Glucagon Sensitivity in Totally Pancreatectomized Patients

IBEN RIX, ASGER LUND, LARS F. GARVEY, KLARA OWEN, CARSTEN HANSEN, GERRIT VAN HALL, JENS J. HOLST, TINA VILSBØLL, FILIP K. KNOP

Diabetes 2021;70(Supplement_1):1191-P

https://doi.org/10.2337/db21-1191-P

Published: 01 June 2021

View article titled, 1191-P: Increased Glucagon Sensitivity in Totally Pancreatectomized Patients

Journal Articles

Glucagonostatic Potency of GLP-1 in Patients With Type 2 Diabetes, Patients With Type 1 Diabetes, and Healthy Control Subjects

Jonatan I. Bagger, Magnus F.G. Grøndahl, Asger Lund, Jens J. Holst, Tina Vilsbøll, Filip K. Knop

Diabetes 2021;70(6):1347–1356

https://doi.org/10.2337/db20-0998

Published: 15 March 2021

View article titled, Glucagonostatic Potency of GLP-1 in Patients With Type 2 Diabetes, Patients With Type 1 Diabetes, and Healthy Control Subjects

Journal Articles

The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition

Sofie Hædersdal, Asger Lund, Elisabeth Nielsen-Hannerup, Henrik Maagensen, Gerrit van Hall, Jens J. Holst, Filip K. Knop, Tina Vilsbøll

Diabetes 2020;69(12):2619–2629

https://doi.org/10.2337/db20-0369

Published: 01 October 2020

View article titled, The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition

Meeting Abstracts

89-LB: The Effect of GIP on Plasma Glucose in a Setting of Prandial Insulin Overdose and Physical Activity after Meal Intake in Patients with Type 1 Diabetes

BJØRN HOE, SEBASTIAN M. NGUYEN HEIMBÜRGER, LÆRKE S. GASBJERG, MADS B. LYNGGAARD, BOLETTE HARTMANN, JENS J. HOLST, TINA VILSBØLL, ASGER LUND, SUSANNE ENGBERG, THOMAS F. DEJGAARD, MIKKEL B. CHRISTENSEN, FILIP K. KNOP

Diabetes 2020;69(Supplement_1):89-LB

https://doi.org/10.2337/db20-89-LB

Published: 01 June 2020

View article titled, 89-LB: The Effect of GIP on Plasma Glucose in a Setting of Prandial Insulin Overdose and Physical Activity after Meal Intake in Patients with Type 1 Diabetes

Meeting Abstracts

1906-P: Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients with Type 2 Diabetes

MIKKEL B. CHRISTENSEN, ASGER LUND, NIKLAS R. JØRGENSEN, JENS J. HOLST, TINA VILSBØLL, FILIP K. KNOP

Diabetes 2020;69(Supplement_1):1906-P

https://doi.org/10.2337/db20-1906-P

Published: 01 June 2020

View article titled, 1906-P: Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients with Type 2 Diabetes

Meeting Abstracts

1052-P: Investigation of the Extrapancreatic Effects of the DPP-4 Inhibitor Sitagliptin: A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial in Totally Pancreatectomized Patients

MILLE BAEKDAL, ASGER LUND, SOPHIE W. NIELSEN, CARSTEN HANSEN, JAN H. STORKHOLM, BOLETTE HARTMANN, JENS J. HOLST, TINA VILSBØLL, FILIP K. KNOP

Diabetes 2020;69(Supplement_1):1052-P

https://doi.org/10.2337/db20-1052-P

Published: 01 June 2020

View article titled, 1052-P: Investigation of the Extrapancreatic Effects of the DPP-4 Inhibitor Sitagliptin: A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial in Totally Pancreatectomized Patients

Meeting Abstracts

10-LB: Dasiglucagon Ameliorates Postprandial Hypoglycemia after Roux-en-y Gastric Bypass

CASPER K. NIELSEN, CAROLINE OEHRSTROEM, URD KIELGAST, DORTE L. HANSEN, ASGER LUND, TINA VILSBØLL, FILIP K. KNOP

Diabetes 2020;69(Supplement_1):10-LB

https://doi.org/10.2337/db20-10-LB

Published: 01 June 2020

View article titled, 10-LB: Dasiglucagon Ameliorates Postprandial Hypoglycemia after Roux-en-y Gastric Bypass

Meeting Abstracts

1140-P: Empagliflozin Attenuates Fasting and Postprandial Hyperglycemia in Totally Pancreatectomized Patients: A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial

MILLE BAEKDAL, ASGER LUND, SOPHIE W. NIELSEN, JAN H. STORKHOLM, CARSTEN HANSEN, TINA VILSBØLL, FILIP K. KNOP

Diabetes 2020;69(Supplement_1):1140-P

https://doi.org/10.2337/db20-1140-P

Published: 01 June 2020

View article titled, 1140-P: Empagliflozin Attenuates Fasting and Postprandial Hyperglycemia in Totally Pancreatectomized Patients: A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial

Meeting Abstracts

1094-P: Short-Acting Exenatide and Markers of Cardiovascular Disease in Type 1 Diabetes: A Randomized, Double-Blinded, Placebo-Controlled Trial

NICKLAS J. JOHANSEN, THOMAS F. DEJGAARD, ASGER LUND, CAMILLA SCHLÜNTZ, EMIL LIST LARSEN, HENRIK E. POULSEN, JENS P. GØTZE, HOLGER MØLLER, TINA VILSBØLL, HENRIK U. ANDERSEN, FILIP K. KNOP

Diabetes 2020;69(Supplement_1):1094-P

https://doi.org/10.2337/db20-1094-P

Published: 01 June 2020

View article titled, 1094-P: Short-Acting Exenatide and Markers of Cardiovascular Disease in Type 1 Diabetes: A Randomized, Double-Blinded, Placebo-Controlled Trial

Journal Articles

Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects With Hepatic Steatosis

Malte P. Suppli, Jonatan I. Bagger, Asger Lund, Mia Demant, Gerrit van Hall, Charlotte Strandberg, Merete J. Kønig, Kristoffer Rigbolt, Jill L. Langhoff, Nicolai J. Wewer Albrechtsen, Jens J. Holst, Tina Vilsbøll, Filip K. Knop

Diabetes 2020;69(6):1090–1099

https://doi.org/10.2337/db19-0715

Published: 23 January 2020

View article titled, Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects With Hepatic Steatosis

Includes: Supplementary data

Journal Articles

Erratum. Evidence of Extrapancreatic Glucagon Secretion in Man. Diabetes 2016;65: 585–597

Asger Lund, Jonatan I. Bagger, Nicolai J. Wewer Albrechtsen, Mikkel Christensen, Magnus Grøndahl, Bolette Hartmann, Elisabeth R. Mathiesen, Carsten P. Hansen, Jan H. Storkholm, Gerrit van Hall, Jens F. Rehfeld, Daniel Hornburg, Felix Meissner, Matthias Mann, Steen Larsen, Jens J. Holst, Tina Vilsbøll, Filip K. Knop

Diabetes 2016;65(6):1752

https://doi.org/10.2337/db16-er06

Published: 18 May 2016

View article titled, Erratum. Evidence of Extrapancreatic Glucagon Secretion in Man. Diabetes 2016;65: 585–597

Journal Articles

Evidence of Extrapancreatic Glucagon Secretion in Man

Diabetes 2016;65(3):585–597

https://doi.org/10.2337/db15-1541

Published: 15 December 2015

View article titled, Evidence of Extrapancreatic Glucagon Secretion in Man

Includes: Supplementary data

NARROW

1651-P: Elevated FGF21 Levels after Total Pancreatectomy and in Response to Single-Dose Glucagon Receptor Antagonism in Humans

801-P: Short-Acting Exenatide Added Three Times Daily to Insulin Therapy Improves Fatty Liver Index in Type 1 Diabetes

745-P: Short-Acting Exenatide Added Three Times Daily to Insulin Therapy Improves Insulin Sensitivity in Type 1 Diabetes

258-OR: The Glucagonotropic Effect of GLP-2 during Hypoglycemia, Euglycemia, and Hyperglycemia in Healthy Men: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study

1192-P: Robust Arginine-Stimulated Glucagon Secretion in Patients with Type 1 Diabetes Independent of Diabetes Duration, Age, HbA1c, and Beta-Cell Secretory Capacity

1191-P: Increased Glucagon Sensitivity in Totally Pancreatectomized Patients

Glucagonostatic Potency of GLP-1 in Patients With Type 2 Diabetes, Patients With Type 1 Diabetes, and Healthy Control Subjects

The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition

89-LB: The Effect of GIP on Plasma Glucose in a Setting of Prandial Insulin Overdose and Physical Activity after Meal Intake in Patients with Type 1 Diabetes

1906-P: Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients with Type 2 Diabetes

1052-P: Investigation of the Extrapancreatic Effects of the DPP-4 Inhibitor Sitagliptin: A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial in Totally Pancreatectomized Patients

10-LB: Dasiglucagon Ameliorates Postprandial Hypoglycemia after Roux-en-y Gastric Bypass

1140-P: Empagliflozin Attenuates Fasting and Postprandial Hyperglycemia in Totally Pancreatectomized Patients: A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial

1094-P: Short-Acting Exenatide and Markers of Cardiovascular Disease in Type 1 Diabetes: A Randomized, Double-Blinded, Placebo-Controlled Trial

Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects With Hepatic Steatosis

Erratum. Evidence of Extrapancreatic Glucagon Secretion in Man. Diabetes 2016;65: 585–597

Evidence of Extrapancreatic Glucagon Secretion in Man

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

This Feature Is Available To Subscribers Only